secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2026-08-17T11:17:57+00:00
Accession:  0001213900-26-090482
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial reports Q2 net loss of $52M; closes Azora acquisition and $32M financing
------------------------------------------------------------------------------

- Net loss of $52.0M ($11.25/share) vs $2.0M loss ($4.61/share) in Q2 2025; includes $46.2M non-cash IPR&D charge.
- Completed acquisition of Azora Therapeutics, adding AT177, an oral colon-targeted AhR agonist for ulcerative colitis; IND planned for H1 2027.
- Closed initial $32M tranche (incl. $5.5M note conversion) of up to $64M private placement; cash $28.7M at June 30 vs $4.6M at March 31.
- G&A expenses rose to $5.4M from $1.2M YoY on merger costs and severance; R&D fell to $440K from $732K.
- Cash runway into H2 2027; stockholders' deficit of $38.4M with $38.5M Series A preferred pending conversion approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026090482/0001213900-26-090482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026090482/ea0301966-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-090482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer